Shares of Tourmaline Oil Corp. TOU slipped 3.33% to C$68.30 Thursday, in what proved to be an all-around poor trading session ...

In a report released on April 3, Michael Harvey from RBC Capital maintained a Buy rating on Tourmaline Oil (TOU – Research Report), with a ...

Tourmaline welcomes back Jeff Zuckerman as Managing Director, who rejoins the firm after four years bringing his expertise ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

Shares of Tourmaline Oil Corp. TOU rose 1.46% to C$70.41 Tuesday, in what proved to be an all-around favorable trading ...

Tourmaline Capital Partners bought the 12-story building for $15 million less than its previous owners acquired it for in ...

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in ...

My last article some years back noted that Charlie Lake had a lot of profit potential, and Tourmaline was there first. As the slide above shows, Charlie Lake has one of the best profit potentials ...

The 14-story complex, called Columbus Center, holds two buildings, one 14 stories and the other eight stories, at 1 Alhambra Plaza in the tony town’s downtown. The Bryn Mawr, Pa.-based investor ...

Biotech Analyst Devarakonda discusses cardiovascular disease with CV expert and Tourmaline Bio management (TRML) on an Analyst/Industry ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.